Document is current
Any future updates will be listed below
-
Authors
Li, Chendi
Syed, Mohammed Usman https://orcid.org/0000-0002-6207-1694
Nimbalkar, Anahita
Shen, Yi
Vieira, Melissa D.
Fraser, Cameron https://orcid.org/0000-0002-8180-5913
Inde, Zintis https://orcid.org/0000-0001-5564-1698
Qin, Xingping https://orcid.org/0000-0003-3263-0843
Ouyang, Jian
Kreuzer, Johannes
Clark, Sarah E.
Kelley, Grace
Hensley, Emily M.
Morris, Robert
Lazaro, Raul
Belmonte, Brian
Oh, Audris
Walcott, Makeba
Nabel, Christopher S.
Caenepeel, Sean
Saiki, Anne Y. https://orcid.org/0000-0003-3913-1860
Rex, Karen
Lipford, J. Russell
Heist, Rebecca S.
Lin, Jessica J. https://orcid.org/0000-0001-7373-3916
Haas, Wilhelm
Sarosiek, Kristopher https://orcid.org/0000-0002-4618-5085
Hughes, Paul E.
Hata, Aaron N. https://orcid.org/0000-0002-6127-318X
- License Information
-
More Information
Article History
Received: 15 January 2025
Accepted: 1 April 2025
First Online: 2 May 2025
Competing interests
: A.N.H. has received research support from Amgen, Blueprint Medicines, BridgeBio, Bristol-Myers Squibb, C4 Therapeutics, Eli Lilly, Novartis, Nuvalent, Pfizer, Roche/Genentech, Scorpion Therapeutics, and Triana Biomedicines; has served as a compensated consultant for Amgen, Engine Biosciences, Nuvalent, Oncovalent, Pfizer TigaTx, and Tolremo Therapeutics. K.S. received research funding from Gate Bioscience and Dialectic Therapeutics. RSH has served as a compensated consultant for Abbvie, Amgen, Astrazeneca, Biohaven, Claim, Daichii Sankyo, EMD Serono, Gilead, Lilly, Merck, Novartis, Regeneron, Sanofi. Research funding to institution, not to self: Abbvie, Agios, Corvus, Daichii Sankyo, Exelixis, Genentech, Lilly, Mirati, Novartis, Turning Point. JJL has served as a compensated consultant for Genentech, C4 Therapeutics, Blueprint Medicines, Nuvalent, Bayer, Elevation Oncology, Novartis, Mirati Therapeutics, AnHeart Therapeutics, Takeda, CLaiM Therapeutics, Ellipses, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Yuhan, Merus, Regeneron, Pfizer, Roche, Gilead, Janssen, Nuvation Bio, Eli Lilly, AstraZeneca, Gilead, and Turning Point Therapeutics; has received institutional research funds from Hengrui Therapeutics, Turning Point Therapeutics, Neon Therapeutics, Relay Therapeutics, Bayer, Elevation Oncology, Roche, Linnaeus Therapeutics, Nuvalent, and Novartis; and travel support from Pfizer, Merus, Takeda, and Bristol Myers Squibb. C.S.N. owns equity (stock) in Opko Therapeutics and has received royalty income from Cambridge Epigenetix. S.C., A.Y.S., K.R., R.L., B.B., J.R.L., P.E.H. are employees of and have ownership (including stock, patents, etc.) interest in Amgen. A.Y.S. also owns stock from Abbvie. The remaining authors declare no competing interests.
